NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Cyclo Therapeutics Inc (NASDAQ: CYTHW)
CYTHW Technical Analysis
5
As on 12th Nov 2024 CYTHW STOCK Price closed @ 0.11 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.32 & Strong Sell for SHORT-TERM with Stoploss of 0.37 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CYTHWSTOCK Price
Open | 0.11 | Change | Price | % |
High | 0.11 | 1 Day | -0.09 | -45.00 |
Low | 0.11 | 1 Week | -0.14 | -56.00 |
Close | 0.11 | 1 Month | 0.00 | 0.00 |
Volume | 1000 | 1 Year | -0.17 | -60.71 |
52 Week High 0.45 | 52 Week Low 0.08 |
NASDAQ USA Most Active Stocks
AMRS | 0.14 | 100.00% |
NVDA | 146.67 | 0.53% |
AKTS | 0.10 | 11.11% |
WORX | 2.12 | 116.33% |
QUBT | 4.76 | 29.35% |
LMDX | 0.02 | 0.00% |
SMCI | 29.70 | 5.06% |
MSTR | 397.28 | -16.16% |
MARA | 23.81 | 22.17% |
CRNC | 5.83 | 106.74% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
CYTHW Daily Charts |
CYTHW Intraday Charts |
Whats New @ Bazaartrend |
CYTHW Free Analysis |
|
CYTHW Important Levels Intraday
RESISTANCE | 0.11 |
RESISTANCE | 0.11 |
RESISTANCE | 0.11 |
RESISTANCE | 0.11 |
RESISTANCE | 0.11 |
RESISTANCE | 0.11 |
RESISTANCE | 0.11 |
RESISTANCE | 0.11 |
CYTHW Forecast November 2024
4th UP Forecast | 0.69 |
3rd UP Forecast | 0.5 |
2nd UP Forecast | 0.39 |
1st UP Forecast | 0.27 |
1st DOWN Forecast | -0.05 |
2nd DOWN Forecast | -0.17 |
3rd DOWN Forecast | -0.28 |
4th DOWN Forecast | -0.47 |
CYTHW Weekly Forecast
4th UP Forecast | 0.24 |
3rd UP Forecast | 0.20 |
2nd UP Forecast | 0.17 |
1st UP Forecast | 0.15 |
1st DOWN Forecast | 0.07 |
2nd DOWN Forecast | 0.05 |
3rd DOWN Forecast | 0.02 |
4th DOWN Forecast | -0.02 |
CYTHW Forecast2024
4th UP Forecast | 0.98 |
3rd UP Forecast | 0.7 |
2nd UP Forecast | 0.53 |
1st UP Forecast | 0.36 |
1st DOWN Forecast | -0.14 |
2nd DOWN Forecast | -0.31 |
3rd DOWN Forecast | -0.48 |
4th DOWN Forecast | -0.76 |
Cyclo Therapeutics Inc ( NASDAQ USA Symbol : CYTHW )
Sector : N/A And Other Stocks in Same Sector
Sector : N/A And Other Stocks in Same Sector
CYTHW Other Details
Segment | EQ | |
Market Capital | 62759980.00 | |
Sector | ||
Industry | ||
Offical website | > echo $website ; ?> |
CYTHW Address
CYTHW Latest News
CYTHW Business Profile
Cyclo Therapeutics, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in October 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida. Address: 6714 NW 16th Street, Gainesville, FL, United States, 32563
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service